Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04778-5 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Geraldine O'Sullivan Coyne und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethes…. Hauptthemen laut MEDLINE: Isoquinolines, Lymphoma, Neoplasms, Topoisomerase I Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CCR NIH HHS, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Purpose
Indenoisoquinolines are a class of topoisomerase I (TOP1) inhibitors designed to overcome clinical limitations of camptothecins. Three indenoisoquinolines (LMP400, LMP776, and LMP744) demonstrated activity in murine models and a comparative canine lymphoma study. Clinical data for LMP400 were previously reported (NCT01051635). The maximum tolerated dose (MTD), safety, and clinical data from phase 1 studies of LMP776 (NCT01051635) and LMP744 (NCT03030417) are reported herein.
Methods
Patients ≥ 18 years of age with advanced, refractory solid tumors or lymphomas received either LMP776 (n = 34) or LMP744 (n = 35) intravenously following a Simon accelerated titration design. Both LMP776 and LMP744 were administered daily for 5 days (QDx5) in 28-day cycles. Adverse events and clinical responses were evaluated according to CTCAE and RECIST v1.1 criteria, respectively. Pharmacokinetic and pharmacodynamic changes were evaluated.
Results
The MTD of LMP776 was 12 mg/m 2 /day and that of LMP744 was 190 mg/m 2 /day. Dose-limiting toxicities (DLTs) for LMP776 included hypercalcemia, anemia, and hyponatremia; DLTs for LMP744 included hypokalemia, anemia, and weight loss. There was 1 confirmed partial response (cPR) among 35 patients receiving LMP744 (overall response rate 3%) and no objective responses in patients receiving LMP776. Tumor biopsies from the patient with cPR demonstrated high baseline expression of SLFN11 and a unique pattern of pharmacodynamic responses, including increased RAD51, phosphorylated KAP1 (pKAP1), γH2AX, and cleaved caspase-3 (cCasp3).
Conclusion
MTDs and safety profiles are reported for LMP776 and LMP744. Target engagement by an indenoisoquinoline was measured for the first time in human samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 3A44, Bethesda, MD, 20892, USA.
- Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
- Biometric Research Program, NCI, NIH, Bethesda, MD, USA.
- Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
- Cancer Therapeutics Evaluation Program, NCI, NIH, Bethesda, MD, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Förderung
- CCR NIH HHS
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
O'Sullivan Coyne, G., Kummar, S., Rubinstein, L. V., Wilsker, D., Moore, N., Hogu, M., Piekarz, R., Covey, J., Beumer, J. H., Ferry-Galow, K. V., Villaruz, L. C., Hollingshead, M. G., Holleran, J. L., Deppas, J. J., Pommier, Y., Ko, B., Johnson, B. C., Parchhment, R. E., Ivy, P., …, & Chen, A. P. (2025). Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04778-5
Vancouver
O'Sullivan Coyne G, Kummar S, Rubinstein LV, Wilsker D, Moore N, Hogu M, et al. Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04778-5
BibTeX
@article{OSullivanCoyne2025,
author = {O'Sullivan Coyne, Geraldine and Kummar, Shivaani and Rubinstein, Larry V and Wilsker, Deborah and Moore, Nancy and Hogu, Murielle and Piekarz, Richard and Covey, Joe and Beumer, Jan H and Ferry-Galow, Katherine V and Villaruz, Liza C and Hollingshead, Melinda G and Holleran, Julianne L and Deppas, Joshua J and Pommier, Yves and Ko, Brian and Johnson, Barry C and Parchhment, Ralph E and Ivy, Percy and Doroshow, James H and Chen, Alice P},
title = {Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04778-5}
}
EUVIMED